What was the primary driver for the decrease in net income compared to the previous year?

The primary driver for the decrease in net income for the quarter was a $100 million pre-tax charge ($63 million after taxes) related to the settlement of litigation with Retractable Technologies, Inc. (RTI).

How did the company's revenue performance vary across its business segments?

All three segments, Medical, Diagnostics, and Biosciences, demonstrated revenue growth. The Medical segment saw a 5% increase in the quarter, Diagnostics grew by 11%, and Biosciences by 12%. International revenue growth was particularly strong, benefiting from favorable foreign currency translation.

What is the company's outlook on its financial health and liquidity?

The company's financial position remains strong, evidenced by robust cash flow from operations of $822 million for the nine-month period and an improved debt-to-capitalization ratio of 26.7%. Management is confident in its ability to meet financial obligations and pursue strategic growth initiatives.

Were there any significant product-related issues or charges impacting the results?

Yes, the company recorded charges related to its blood glucose monitoring (BGM) products in a prior period, including a voluntary recall of certain test strips and the write-off of inventory. The current period's results were primarily impacted by the RTI litigation settlement.

BDX 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported its third-quarter and year-to-date results for the period ending June 30, 2004. The company demonstrated solid revenue growth across its key segments, Medical, Diagnostics, and Biosciences, with overall revenues increasing by 8% year-over-year for the quarter and 11% for the nine-month period. This growth was driven by strong performance in safety-engineered devices and international markets, although currency fluctuations had a notable positive impact on reported international revenue growth. A significant event during the quarter was the $100 million litigation settlement with Retractable Technologies, Inc. (RTI), which impacted net income and earnings per share. Despite this charge, the company maintained a strong balance sheet, with a reduced debt-to-capitalization ratio and robust cash flow from operations. Management continues to focus on strategic initiatives aimed at revenue growth through product innovation, geographical expansion, and operational efficiency.

Key Highlights

1Total revenues increased by 8% to $1.258 billion for the three months ended June 30, 2004, and by 11% to $3.728 billion for the nine months ended June 30, 2004.
2The company paid a $100 million pre-tax charge ($63 million after taxes) to settle litigation with Retractable Technologies, Inc. (RTI), impacting diluted EPS by approximately $0.24.
3Net income for the quarter decreased to $109 million ($0.41 per diluted share) from $130 million ($0.49 per diluted share) in the prior year, primarily due to the litigation settlement.
4Cash flow from operations remained strong, with $822 million generated for the nine months ended June 30, 2004, supporting capital expenditures and debt management.
5The debt-to-capitalization ratio improved to 26.7% at June 30, 2004, down from 30.4% at September 30, 2003.
6The Medical and Diagnostics segments showed steady revenue growth, while the Biosciences segment experienced significant increases driven by new product launches and strong reagent sales.
7The company continues to repurchase its common stock, with approximately $350 million spent on repurchases during the nine-month period.

BECTON DICKINSON & CO Quarterly Report for Q3 Ended Jun 30, 2004

Summary

Key Highlights

Frequently Asked Questions